Slides
Page 1
January 15, 2025 Jerrell Shelton, CEO
Page 2
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport’s anticipation of continued growth in its services business and ongoing softness in product sales; Cryoport’s plans and expectations relating to its previously announced cost reduction and capital realignment strategies, including Cryoport’s plans to complete these adjustments by the year's end and Cryoport’s belief that these measures will lead to a return to positive adjusted EBITDA during 2025; Cryoport's expectations that the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue into the near future; and Cryoport's belief that it is strategically positioned to leverage the anticipated long-term growth in the Cell & Gene therapy market through Cryoport’s comprehensive and integrated supply chain solutions. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties include difficulties, delays or Cryoport's inability to successfully complete its planned cost reduction and capital realignment measures, which could reduce the benefits realized from such activities within the time periods currently anticipated. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Forward Looking Statements © 2025 CRYOPORT, INC. 2
Page 3
3© 2025 CRYOPORT, INC. Cryoport Platform Solutions Infrastructure and Information Technology is crucial to the cell & gene therapy (C>) industry as it provides the foundation for its development and growth by enabling and facilitating efficient production and supporting innovation, essentially acting as the backbone for the industry to develop and operate effectively. Without adequate infrastructure it will be very hard for cell & gene therapies to scale on a global basis. Cryoport’s fully integrated, advanced supply chain platform is a key piece of the supporting infrastructure for C>.
Page 4
© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services Cryoport’s Infrastructure for the C> Workflow 4 Assembly Options / Secondary Labeling, Packaging Solutions Collection/Cryopreservation Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps IntegriCell Platform
Page 5
© 2025 CRYOPORT, INC. Cell Therapy Market November 2024 Allogeneic CAR-T Marketed Filed TCR GSK GSK3377794 NY-ESO-1 NK TIL Squibb GileadSciences ImmaticsNV PRAME IMA203CD8 PRAME,CD8 TRuC Breyanzi CD19(LBCL) Novartis Kymriah CD19 Tabelecleucel (Multi -cohort EBV) CD19 M-ceNK Acepodia ACE1702 HER2 Adaptimmune Therapeutics TC-510 Mesothelin TC-520 CD70 TscanTherapeutics TSC-100 HA-1 TSC-101 JNJ/ LegendBiotechAbecma BCMA MustangBio MB-101 IL13Rα2 Γδ IN8Bio INB-100 INB-200 Acepodia ACE1831 CD20 TAK-102 GPC3 TAK-103 Mesothelin TAK-940 CD19 Amgen AMG119 BristolMyers CNCT19 CD19 Pivotal CD22 CD123 CARsgen Therapeutics Zevor-cel BCMA Autolus AUTO1/22 Obe-cel CD19 Therapeutics CTX112 MUC16 PRGN-3006 CD33 Takeda PRGN-3007 BioNTech BNT221 Anixa FSHR Autologous CAR-T Arcellx ACLX-001CD4/CD8 2SeventyBio DLL3 Affymmune CD19 Therapeutics CTX130 SC-DARIC33 ICAM-1 Atara BiosciencesbbT369 CD79/CD20 ATA2271 Mesothelin Carvykti BCMA Autolus Aucatzyl CD19 Tecartus CD19(MCL) Yescarta CD19 AvenCell Europe AVC101 Biosciences AIC100CD123 BNT211 AUTO8 BeijingImmuchina CLDN6 BCMA,CD19 Pharmaceuticals IM19 CD19 BeijingImmuchina Pharmaceuticals IM19 CD19(DLBCL) ROR-1 CAR-T ROR-1 CD19 BristolMyersSquibb Breyanzi CD19(MCL,CLL,MZL) Pharmaceutical CARsgen CLBR001+ SWIO19 Therapeutics CTO11 GPC3 CLDN18.2 Cellular CT0590 CT0180 ChimericCT0181Therapeutics CLTX CHM2101 BiomedicineBCMA KITE-222 CLL-1 KITE-363 GPRCD5 CD19/CD20 GPRCD5 CART-TnMUC1 MUC1 GalapagosNV TmFRa01 Fra 5101 TmPMSA01 PSMA CD19 MUC-1 IASOBiotherapeutics CT103A BCMA CD19/CD20 RD125 CD5 RD133 RD138 HemeBispecific CD19/CD20 BCMA InnvoativeCellular Precigen Therapeutics GCC BristolMyersSquibb LyellImmupharma LYL797 Noile-Immune ImmPACTBioBiotech NIB101 GM2 Novartis 5201 TmTN-MUC01 YTB-323 CD19 JEZ567 CD123 Minerva BiotechnologiesOriCell Therapeutics huMNC2-CAR44 MUC-1 OriCAR-017 GPRC5D Ori-C101 GPC3 PeproMeneBio PMB-101 BAFR HER2+ Vor Biopharma CD19 VCAR33 CD33 Therapeutics UCARTCS1 ALLO-316 CS1,SLAMF7 CD70 UCART22 ALLO-715CRSPR BCMA UCART19 CB-010 CD19 CB-011 BCMA Allogene Cema-cel CD19 Chongqing CD70CAR-T CD70 IMA201 IBI345 CLDN18.2 Biosciences PoseidaTherapeutics P-BCMA-ALLO1 BCMA P-MUC1C-ALLO1 CD30 PrecisionBiotech BioSciences PBCAR19B CD19 SorrentoTherapeutics InnoventBiologics CD38DAR-T CD30 AFP Adaptimmune Therapeutics Afami-cel MAGE-A4 HA-1 KairosPharma Lion TCR HBV NeoTCR-P1 GPC3 PactPharma KROS-201 MAGE-A4 Bioscience 800TCR GadetaBV HighPassBio HERV-E MAGEA4/8 HA-1 TCR IMA203 KK-LC-1 T-Knife GmbH TK-8001 MAGE-A1 AdicetBio ADI-001 CD20 INB-400 ADI-002 OmnImmune GPC3 TCB002 Affimed NV AFM24-103 EGFR BiotherapeuticsImmunityBio AB-101 PD-L1 T-haNKCD20mAb AB-201 HER2 CYNK-001 CYNK101+mAb Chimeric Therapeutics CHM0201 FateTherapeutics BCMA,CD38 Inaleucel Deverra Therapeutics DVX201 CD19 MiNK Therapeutics agenT-797 invIOs NKX019 CD19 APN401NKX101 NKGenBiotech Ceullularity SNK01 SNK02 Cbl-b NKG2D Sanofi SAR445419 NK Cells Iovance Biotherapeutics IOV-2001 IOV-4001 Iovance Biotherapeutics LN-145 Nurix Therapeutics DeTIL-0255 Lyell Immupharma LYL845 Iovance Biotherapeutics Amtagvi LN-144 Atara Biotherapeutics Tabelecleucel (EBV) T-Cell (Other) Eutilex 4-1BBCTL (Lymphoma) (SolidTumors)Marker Therapeutics 4-1BBCTL MT-601 Multiple Antigen NexImmune NEXI-002 Multiple Antigen AdaptimmuneTherapeutics Gavo-cel Mesothelin Eureka CDH17 Therapeutics GileadSciences ARYA3-ECT204 GPC3 BCMA BCMA ET140203 AFP BristolMyersSquibb GPRCD5 GPRCD5 CD70 CellSource CD33 CD19 Anti-Viral CTX131 VETOCell CD70 WUGEN TT11X TactivaTherapeutics TCREngineeredT-Cells SAR444200 NY-ESO-1, CD4,CD8 Celularity CYNK-001 (AML, MM) Glycostem GamidaCell GDA-201 NK Cells WUGEN WU-NK-101 NexImmune NEXI-001 NEXI-002 Multiple Antigen HBV Smart Immune Atara BiotherapeuticsSMART101 TriumviraImmunologics TAC101-CLDN18.2 R/R CLDN18.2Tumors PhaseII ObsidianTherapeutics FT576 OBX115 iPSC AstraZeneca AZD0120 BCMA/ CD19 Myeloid Carisma Therapeutics CT-0508 HEr2 EnlivexTherapeutics Allocetra BAI,TIM4, Stabilin 2, Annexin V MT-101 CD5 MaxiVAXSA MVX-ONCO-1 GM-CSF NKT KUR-501 GD2 KUR-502 CD19 CD19 A2 Biotherapeutics A2B530CT041 CHM1101 CEA Adaptimmune Therapeutics HiT Mesotehlin MAGE-A4 LionTCR Affimed NV AFM13-104 AlphageneronCD30 Takeda Pharmaceuticals Pharmaceutical Enkastim mHsp70 TAK-007 Arcellx autoleucel BCMA CASIPharmaceuticals Atara UCART123Biotherapeutics ATA3219 CD19 Athenex TCR-NKT P53,KRAS,EGFR Nkarta Caribou BeamTherapeutics MUC-1 CB-012 BEAM-201 TessaTherapeutics LCC-1 (CD371) CD7 Orgeenesis ORGCAR19 CD19 CD19+ CD22 ORGCAR19.22 AUTO4 CD19/CD22 TRBC1 WU-CART-007 PoseidaTherapeutics P-CD19CD20-ALLO1 CD19/ CD20 Adaptimmune TherapeuticsSanaBiotechnology ADP-A2AFP SC291 CD19 ADP-A2M4CD8 T-Cure 820TCR GDT-002 TscanTherapeutics γδ TCR SCGCellTherapy TSC-201 SanofiSCG101 TSC-203 GPC3 TSC-204 Marker HA-2 Therapeutics MANA Therapeutics MT-1202 MT-401 OTS MANA-312 MAGE-A4,PRAME, PRAME,WT-1, SurviviSnurvivin,NY-ESO-1, SSX2 Eutilex NexImmune NEXI-003 CD3+/ CD4- CT-120 LegendBiotechROR1 TessaTherapeutics LB1908 CLDN18.2 EurekaTherapeutics ETO19003TT16 CD19/ CD22 ROR1 ROR1TCBioPharm (ARS,MM, Solid TumFoarst)eTherapeutics CenturyTherapeutics Athenex CNTY-101 FT825/ Ono HER2 FT819 CD19 GICell CARNK MyeloidTherapeuticGsIC-101 (nanoNK) GIC-201 (TOPNK) CD16 Artiva Note: PhaseI data asof May‘24; PhaseII+ asof November ‘24 Source:Companywebsitesandfilings, Biomedtracker CARGOTherapeuticsAnitocabtagene CRG-022 CD22 AbelZeta C-CAR066 CD20 AbelZeta C-CAR039 CD19/CD20 Lyell immunopharma IMPT-314 CD19/CD20 IN8Bio Legend Biotech LCAR-AI0 PRGN-3005 GCC19CART CD19/CD20/CD22 UCART20x22 CD20/CD22 CTX110 CD19 2SeventyBio Precision Allogene Precision CellectisPhaseI BioSciences Azer-cel Cellectis CD19 Oncternal Group Therapeutics C-CAR088 BCMA Elpis ONCT-808 Biopharmaceuticals ROR1 © 2025 Wells Fargo Bank, N.A. All rights reserved. Confidential. 5
Page 6
6© 2025 CRYOPORT, INC. Gene Therapy Market April 2024
Page 7
7© 2025 CRYOPORT, INC. C> Supply Chain Leader Performance Global Platform (2) Source: Company Filings and materials Notes: (1) Supported by Cryoport Systems as of 9/30/2024 (2) As of 9/30/2024 $56.7M Q3-2024 Revenue 17 Commercial Cell & Gene Therapies Supported (1) 3,000+ Global Clients $6.1M 11% of total revenue Commercial Cell & Gene Therapies revenue $225 - $235M FY 2024 Revenue Guidance $273M Cash & Short-Term investments 50+ Facilities in 17 Countries 1,100 Employees Cryoport – Q3 2024 Snapshot 691 Active Cell & Gene Therapy Clinical Trials Supported (2)
Page 8
8© 2025 CRYOPORT, INC. Client-Focused Solutions Market Leader Category Temperature-controlled Supply Chain Life Science Specialty Courier Cryogenic Systems Biostorage Temperature-controlled supply chain solutions Biologistics & packaging Bioservices IntegriCellTM Consulting Temperature-controlled premium specialty courier solutions Direct-to-patient Pick and pack preparation Onboard courier Cryogenic biostorage solutions Cryogenic transportation solutions Innovative cassettes and racks Temperature-controlled biostorage services Sample processing and distribution Validated lab information system Emergency backup services • 17 commercial therapies • 691 Clinical trials • 55k+ annual shipments • 150+ countries • 10 facilities • 150+ qualified agents worldwide • 3M+ patients served • 1M+ shipments • 30 depots • 3 facilities • 60 years of setting the standard for cryogenic systems products and services • 84,000 sq ft facility in Houston • 10,000 sq ft facility in San Antonio • 30,000 sq ft facility under construction soon • 24-hour turnaround for pick/pack shipments Key CapabilitiesKey Figures
Page 9
© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services 9 Assembly Options / Secondary Labeling, Packaging Solutions Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps Cryoport Systems is a Fully Integrated C> Supply Chain Solution Collection/Cryopreservation IntegriCell Platform
Page 10
10© 2025 CRYOPORT, INC. Source: Company materials cross-referenced to clinical trial information publicly available 691 clinical trials (net) in aggregate 79 Phase III trials in the Americas, EMEA and APAC Clinical Trials Supported by Trial Phase as of 9/30/24 Increased by 21 trials (net) over Q3 2023 Cryoport Systems Supports a Growing Cell & Gene Therapy Clinical Trial Pipeline
Page 11
11© 2025 CRYOPORT, INC. Cryoport Supports 17 Commercial Cell & Gene Therapies AKUUGO®
Page 12
12© 2025 CRYOPORT, INC. Cryoport Systems’ Proprietary Shipper Fleet Cryoport Elite 28L Ultra Cold Shipper ELUC128 -60° C to -80° C Cryoport Elite 56L Ultra Cold Shipper ELUC156 -60° C to -80° C CryoMax® Cryogenic Lab Move Shipper C1536PD 21 days at -150°C or colder Cryoport Express ® High Volume Dry Vapor Shipper CXHV3 -150° C or colder
Page 13
13© 2025 CRYOPORT, INC. Managed Through Live View Cryoportal® 2 Logistics Management Platform & Smartpak II® Condition Monitoring System
Page 14
14© 2025 CRYOPORT, INC. Providing Crucial Information Regarding Conditions Supporting Efficacy Chain of Custody Traceability of the custody of each client’s/patient's therapy Chain of Condition Traceability of the condition of each client’s/patient's therapy Chain of Identity Traceability of the identity of each client’s/patient's therapy Chain of Compliance® Traceability of the equipment and processes supporting each client’s/patient's therapy
Page 15
15© 2025 CRYOPORT, INC. GMP BioStorage Regulatory & Consulting Services Biobanking Clinical Sample Management Logistics Management Services Drug Packaging & Labelling Kit Production Drug Recall, Return, & Destruction Cryoport Systems’ BioServices
Page 16
16© 2025 CRYOPORT, INC. IntegriCell - a Unique Platform for Starting Materials A standardized cryopreservation and distribution solution for the global cell therapy market located in Villers le Bouillet, Belgium and Houston, Texas Collection Cryopreservation Storage & Distribution Standardization and integration to Chain of Compliance ® Apheresis Partners • ONE Contract, ONE Quality Management Agreement, ONE Audit • Removes Risks, Decreases Costs, and Improves Quality Global Supply Chain Centers
Page 17
17© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services Assembly Options / Secondary Labeling, Packaging Solutions Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps CRYOPDP is One of the Largest Specialty Couriers in the World Collection/Cryopreservation IntegriCell Platform
Page 18
18© 2025 CRYOPORT, INC. CRYOPDP in one page Backed by a team of experienced professionals in the logistics and cold chain market. Focused on Life Science and Healthcare +3M Patients served together with our partners every year +4K Customers trust us 360k+ Shipments per year 39 Facilities 16 Countries We provide customized solutions tailored to meet our customers’ needs. With an extensive offer from packaging, to transport and added value solutions CRYOPDP facilities span 16 countries, encompassing 39 locations across the US, EMEA and APAC regions. Committed to providing temperature-controlled logistics and supply chain solutions
Page 19
© 2025 CRYOPORT, INC. CRYOPDP - Adds To Our Growing Global Unified Network CRYOPDP Locations MVE Biological Solutions Locations April 2021 Acquisition of CTSA, Australia Cryoport Systems Locations Cryogene Location 19 HQ July 2022 Acquisition of Polar Expres, Spain May 2021 Acquisition of F-airGate, Belgium 39 locations in 16 countries December 2024 Acquisition of Bluebird Express, US
Page 20
© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services MVE Biological Solutions Cryogenic Systems Support C> Workflow 20 Assembly Options / Secondary Labeling, Packaging Solutions Collection/Cryopreservation Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps IntegriCell Platform
Page 21
© 2025 CRYOPORT, INC. The Leading Cryogenic Systems Manufacturer in the World 60 years of setting the standard for cryogenic storage Global leader in the provision of cryo- systems in the life sciences industry Headquarters: Ball Ground, GA 270 employees globally MVE Biological Solutions is the leading manufacturer of cryogenic systems, providing cryogenic freezers, dewars, and related equipment used for cryogenic storage and transportation • Three primary locations o Ball Ground, GA o New Prague, MN o Chengdu, China 21
Page 22
22© 2025 CRYOPORT, INC. MVE’s Product Family CRYOGENIC FREEZERS Ball Ground, GA Bulk storage stainless-steel freezers in a range of sizes and configurations Basic bulk storage stainless-steel freezer for the breeder market CRYOGENIC DEWARS New Prague, MN Complete portfolio of aluminum dewars for sample storage, sample shipping, and LN2 storage CRYOGENIC DEWARS Chengdu, China Complete portfolio of aluminum dewars for sample storage, sample shipping, and LN2 storage
Page 23
© 2025 CRYOPORT, INC. Innovations: Vario and Fusion 23 Vario Freezer • Variable temperature LN2 freezer: - 20C to -190C • LN2 flows through controlled actuated heat exchangers to achieve the desired temperature • Utilizes minimal electricity • Greater sample security than a mechanical freezer due to superior thermodynamic properties • Fill using controller Fusion Freezer • Self sustaining LN2 freezer • Operates between -160C & - 170C • Utilizes minimal electricity compared to mechanical freezers • Perfect for locations where LN2 access is challenging • Fill using transfer hose initially plus top off to counter thermal addition
Page 24
24© 2025 CRYOPORT, INC. MVE Biological Solutions’ FDA Registration
Page 25
© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services CRYOGENE Supports Pre-clinical C> Workflow 25 Assembly Options / Secondary Labeling, Packaging Solutions Collection/Cryopreservation Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps IntegriCell Platform
Page 26
© 2025 CRYOPORT, INC. • Secure GMP Compliant Biorepository – Liquid Nitrogen (at or below -150ºC) – Mechanical Freezers (4C, -20ºC to -80ºC) – Controlled room temperature – Storage for bulk biopharma materials • FDA Registered • 84,000 sq ft facility in Houston • ISO 9001 Quality Management System • 24-hour Turn Around for Pick/Pack Shipments • Sample Processing • Sample Transportation • Final Product Processing • Opened San Antonio in 2024 • Moffitt/Speros construction in 2025 One of The Largest, Most Comprehensive Biostorage Operations in U.S. 26
Page 27
27© 2025 CRYOPORT, INC. CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center • 30,000 sq ft facility with exclusivity for biorepository services • Construction to begin Q2 2025 • Biological material transfers begin Q2 2026 • CRYOGENE will provide our services to biotech, research, and pharma companies in the region • 775-acre Speros Clinical Research Campus in Tampa, FL
Page 28
© 2025 CRYOPORT, INC. Biostorage & Supply Chain Services Cryoport’s Infrastructure for the C> Workflow 28 Assembly Options / Secondary Labeling, Packaging Solutions Collection/Cryopreservation Fulfillment & Kit Production Patient Delivery Biostorage & Supply Chain Services Temperature-controlled Shippers Therapeutic Manufacturing Biopharma / CDMO Partnership with Cryoport Cryoport Capabilities Other Cell Therapy Value Chain Steps IntegriCell Platform
Page 29
29© 2025 CRYOPORT, INC. Cryoport’s ESG and Sustainability Framework To protect the health and safety of current and future generations through supply chain solutions that promote sustainability, resilience, and respect for the environment. Mission Cryoport’s mission is to support life and health by providing reliable and comprehensive temperature-controlled supply chain solutions for the life sciences through its advanced technologies and dedicated personnel. Cryoport will strive to develop mutually rewarding relationships with its employees, clients, partners and suppliers and to conduct its business to the highest ethical and professional standards. Science. Supply Chain. Certainty. Delivering sustainable operations Supporting our people Innovating responsibly Governing ethically Vision ENABLING A HEALTHIER, SUSTAINABLE FUTURETheme Pillars • GHG Emissions • Resource Efficiency • Diversity, Equity & Inclusion • Employee Health & Safety • Product & Service Quality • Product Lifecycle Management & Innovation • Business Ethics • Supplier Management • Data Privacy & Security Focus Areas
Page 30
30© 2025 CRYOPORT, INC. 30 What’s Ahead for Cell & Gene Therapies © 2025 CRYOPORT, INC.
Page 31
CRYOPORT © 2025 CRYOPORT, INC. Cell & Gene Therapy Accelerating Toward a Therapeutic Revolution Note: 1. As of December 2024; excludes cord blood products Chronology of Key Developments First generation CARs developed 1993 1990 First clinical trial using viral vector Second generation CARs developed 1998 First effective CAR T cells developed 2002 2003 First regulatory approval of Gene therapy product (China) First clinical data using CAR T 2010 2012 Approval of first Gene therapy in E.U. 2016 First ex vivo Gene therapy product approved in E.U. Development of CRISPR / Cas9 technology 2013 FDA approval of first CAR-T cell therapy 2017 FDA approval of CD19 CAR-T therapy 2021 2019 First Gene therapy product approved in U.S. Current 18 FDA approved Gene Therapy Products (1) FDA approved Cell Therapy Products (1) 16 Current Cell Therapy Gene Therapy Up to 18 BLA/MAA Filings in 2025 2022 FDA Approval of BCMA-targeted CAR—T cells 2023 First CRISPR– Cas9 technology Source: Wall Street Research, Genehome, American Society of Cell and Gene Therapy, Alliance for Regenerative Medicine, FDA 31
Page 32
CRYOPORT Volume and Stage of Clinical Activity Suggest Pace of Innovation Will Only Increase Growth in Cell and Gene Therapy Trials (1) Global Cell & Gene Therapy Pipeline (# Programs) 510 1,785 105 398 215 467 50 62 880 2,855 7,800 0 2,000 4,000 6,000 8,000 2016A 2023A 2027E Pre Clinical Phase 1 Phase 2 Phase 3 Source: clinicaltrials.gov, Gene Cell & RNA Therapy Landscape Report from ASGCT, L.E.K. LP Innovation is Leading the Way, with Preclinical and Phase 1 Activity in 2023 Having Grown 3.5x Over 2016 and Total Growth Forecast to be Over 8.8X 2016 by 2027 Notes: 1. Filtration criteria includes industry-sponsored studies posted from Jan 1 to Dec 31 of each respective year 2. Phase 3 includes pre-registration assets (2) 32
Page 33
CRYOPORT © 2025 CRYOPORT, INC. $0.4 $0.5 $1.4 $2.7 $4.2 $5.3 $6.8 $8.6 $10.9 $14.5 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 1 2 1 1 2 4 4 7 8 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Cell & Gene Therapy Commercial Pipeline Continues to Progress Global Cell & Gene Therapy Sales ($Bn) Annual C> FDA Approvals (1) Note: 1. Excludes cord blood approvals; 3 approvals before 2015 Source: FDA, Evaluate Pharma; data as of December 2024 33
Page 34
Evaluate’s Expected 20-Year Growth Trend: Regenerative Medicine Compared to Biologics © 2025 CRYOPORT, INC. 34 Source: Evaluate LTD C> Drug Approval expected to accelerate with C> commercial revenue to ramp similar to Biologics
Page 35
CONFIDENTIAL | 35© 2025 CRYOPORT, INC. Thank You!
Page 36
© 2025 CRYOPORT, INC. Appendix
Page 37
37© 2025 CRYOPORT, INC. Revenue by Type
Page 38
38© 2025 CRYOPORT, INC. Statement of Operations
Page 39
39© 2025 CRYOPORT, INC. Adjusted EBITDA
Page 40
40© 2025 CRYOPORT, INC. Balance Sheet Cash and Investments: $272.7M
Page 41
41© 2025 CRYOPORT, INC. Upcoming Investor Conferences Host Conference Date Location J.P . Morgan Healthcare Conference January 13-16, 2025 San Francisco, CA Needham Annual Growth Conference January 17, 2025 Virtual BTIG Annual MedTech February 11-12, 2025 Snowbird, UT Leerink Global Healthcare Conference March 10-12, 2025 Miami, FL Roth Annual Growth Conference March 17-19 Dana Point, CA KeyBanc Healthcare Forum March 18-19 Virtual Needham Healthcare Conference April 7-10 Virtual